Form 4: Adverum CFO's Equity Transactions Post-Eli Lilly Merger

Adverum Biotechnologies' CFO, Linda M. Rubinstein, reported significant stock and option transactions following the company's acquisition by Eli Lilly and Company, effective December 9, 2025.

Summary

• Adverum Biotechnologies, Inc. completed its merger with Eli Lilly and Company's subsidiary, Flying Tigers Acquisition Corporation, effective December 9, 2025, making Adverum a wholly-owned subsidiary of Eli Lilly.
• As part of the merger, Adverum stockholders received $3.56 per share in cash and one non-tradable contingent value right (CVR) per share, with potential aggregate payments of up to $8.91 per CVR.
• Linda M. Rubinstein, Chief Financial Officer, exercised 48,750 stock options at an exercise price of $4.2 per share on December 9, 2025.
• Rubinstein's 61,150 shares of common stock, 8,125 restricted stock units (RSUs), and 42,000 performance stock units (PSUs) were disposed of in connection with the merger, converted into cash consideration and CVRs.
• Prior to the merger, 42,000 performance stock units vested due to the change of control event.
• All outstanding 'out-of-the-money' stock options (exercise price equal to or greater than the cash consideration) held by Rubinstein, totaling 182,083 options with exercise prices of $10.14 and $7.15, were fully vested and then cancelled for no consideration at the effective time of the merger.

Sentiment

Score: 7

Explanation: The filing reflects the successful completion of a merger, providing shareholders with cash and potential future value through CVRs. While out-of-the-money options were cancelled, the overall event represents a positive liquidity event for the company's equity holders, albeit with the loss of independent public company status.

Positives

• The merger provides a clear exit strategy for Adverum shareholders, offering immediate cash consideration of $3.56 per share.
• Shareholders, including the CFO, received Contingent Value Rights (CVRs) which offer potential future cash payments of up to an aggregate of $8.91 per CVR upon achievement of specified milestones, providing additional upside potential.
• The vesting of 42,000 performance stock units for the CFO due to the change of control event allowed for their conversion into merger consideration.

Negatives

• Out-of-the-money stock options with exercise prices of $10.14 and $7.15, totaling 182,083 options, were cancelled for no consideration, resulting in a loss of potential value for the option holder.
• Adverum Biotechnologies, Inc. ceased to be an independent publicly traded company, becoming a wholly-owned subsidiary of Eli Lilly and Company.

Risks

• The contingent cash payments associated with the CVRs are not guaranteed and are dependent on the achievement of specified milestones, introducing uncertainty regarding their ultimate value.

Future Outlook

Adverum Biotechnologies, Inc. is now a wholly-owned subsidiary of Eli Lilly and Company, and its future operations and strategic direction will be integrated within Eli Lilly's broader corporate strategy. The future value for former Adverum shareholders who received CVRs is contingent upon the achievement of specified milestones.

Management Comments

• The Chief Financial Officer's equity holdings were converted or cancelled in accordance with the terms of the merger agreement, reflecting the company's transition to a wholly-owned subsidiary.

Industry Context

This acquisition by Eli Lilly and Company reflects a broader trend in the biotechnology and pharmaceutical industry where larger, established companies acquire smaller firms to expand their pipeline, gain access to new technologies, or consolidate market positions. The use of CVRs is a common mechanism in such deals to bridge valuation gaps or share future development risks and rewards.

Comparison to Industry Standards

• The acquisition structure, including a cash component and contingent value rights (CVRs), is a common approach in the biotech industry for deals involving companies with pipeline assets that have future development milestones. This allows the acquirer to mitigate risk while providing potential upside to the acquired company's shareholders.
• The cancellation of out-of-the-money options for no consideration is standard practice in mergers where the acquisition price is below the option's exercise price, aligning with typical industry deal terms.
• The vesting of performance stock units upon a change of control is a common provision in equity incentive plans, designed to provide liquidity and reward employees in such events, consistent with practices seen in comparable biotech acquisitions.

Corporate Governance

Related Party Transactions

• The merger itself constitutes a significant transaction between Adverum Biotechnologies, Inc. and Eli Lilly and Company (through its subsidiary), resulting in Adverum becoming a wholly-owned subsidiary.

Stakeholder Impact

• Shareholders: Received cash consideration and CVRs for their shares, providing liquidity and potential future upside.
• Employees (including CFO): Equity awards (RSUs, PSUs, stock options) were converted or cancelled according to merger terms, impacting their personal holdings.
• Company (Adverum): Ceased to be an independent public entity, now operating as a subsidiary of Eli Lilly, with its strategic direction integrated into the parent company.

Next Steps

• Monitoring the achievement of specified milestones for the contingent value rights (CVRs) to determine if additional cash payments will be made to former Adverum shareholders.

Key Dates

Keywords

Adverum Biotechnologies, ADVM, Eli Lilly, Merger, Acquisition, Form 4, Insider Trading, CFO, Stock Options, RSU, PSU, Contingent Value Right, CVR